Media

Home
Media

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

bcalitri@ironwoodpharma.com

Sort by Year

November 6, 2018

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

October 25, 2018

Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call

October 8, 2018

Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

September 13, 2018

Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

August 28, 2018

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 21, 2018

Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

August 6, 2018

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

July 23, 2018

Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call

July 16, 2018

Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

June 23, 2018

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions

June 21, 2018

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

June 20, 2018

Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions

June 7, 2018

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease

June 6, 2018

Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

June 5, 2018

Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018

Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.